Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$77000.0.

  • NovaBay Pharmaceuticals' Other Non Operating Income fell 49230.77% to -$77000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$256000.0, marking a year-over-year increase of 4869.74%. This contributed to the annual value of -$550000.0 for FY2024, which is 4905.15% down from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Other Non Operating Income stood at -$77000.0 for Q3 2025, which was down 49230.77% from -$97000.0 recorded in Q4 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Other Non Operating Income peaked at $342000.0 during Q4 2022, and registered a low of -$1.6 million during Q4 2021.
  • Moreover, its 5-year median value for Other Non Operating Income was -$69000.0 (2024), whereas its average is -$176538.5.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Other Non Operating Income surged by 1085000.0% in 2022 and then tumbled by 1430000.0% in 2023.
  • NovaBay Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$1.6 million in 2021, then soared by 121.66% to $342000.0 in 2022, then crashed by 81.58% to $63000.0 in 2023, then tumbled by 253.97% to -$97000.0 in 2024, then increased by 20.62% to -$77000.0 in 2025.
  • Its last three reported values are -$77000.0 in Q3 2025, -$97000.0 for Q4 2024, and -$13000.0 during Q3 2024.